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Abstract
Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and
therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system
disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected
people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and
financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is
immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling
nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic
applications for degenerative, inflammatory and infectious disorders of the nervous system. This review
focuses on the current and future potential of the field to positively affect clinical outcomes.
From the Clinical Editor
Many nervous system disorders remain unresolved clinical problems. In many cases, drug agents simply
cannot cross the blood-brain barrier (BBB) into the nervous system. The advent of nanomedicines can
enhance the delivery of biologically active molecules for targeted therapy and imaging. This review focused on
the use of nanotechnology for degenerative, inflammatory, and infectious diseases in the nervous system.
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Abstract
Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric,
developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant
societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver,
and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A
means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range
from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the
nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.
From the Clinical Editor: Many nervous system disorders remain unresolved clinical problems. In many cases, drug agents simply cannot
cross the blood-brain barrier (BBB) into the nervous system. The advent of nanomedicines can enhance the delivery of biologically active
molecules for targeted therapy and imaging. This review focused on the use of nanotechnology for degenerative, inflammatory, and
infectious diseases in the nervous system.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The field of nanoneuromedicine offers real opportunities to
harness unique therapeutic approaches to address diseases of the
nervous system where often few options exist. Because of the
enormous potential of the field, it was chosen as the theme for the
2014 meeting of the American Society for Nanomedicine.1 In
addition to improved therapies, newer, safer and more
sensitive-specific imaging modalities as well as improved
diagnostics for disease detection are immediately needed.
Nervous system disorders, due to infection, trauma or
degenerative disorders, represent a significant societal burden
with parallel broad unmet needs. In many and sometimes most
cases, current treatments are simply inadequate to affect disease
progression or even ameliorate symptoms and signs of brain
injury or degeneration. Significant challenges abound and are
associated with the transport of therapeutic or imaging contrast
agents across the blood–brain barrier (BBB) into the nervous
system and retain the ability to achieve targeted delivery to
appropriate brain or spinal cord subregions.2 Nanomedicines can
facilitate solutions to such problems. This and related enabling
technologies, can increase drug–drug interactions, facilitate
disease ameliorating immunomodulation, enable pathogen
clearance and improve nervous system delivery of biologically
active molecules. Included are multifunctional therapeutic,
imaging and diagnostic devices currently referred to as
theranostics.3 However, limitations for improved drug delivery
to the nervous system are not trivial, including the potential for
secondary toxicities. Thus, any new formulation must balance a
drug therapeutic index. This highlights a quite diverse and
multifaceted field of research in biomarker discovery, bioima-
ging and theranostics. If successful, therapies to address
neurodegenerative, immune and infectious diseases of the
nervous system could be realized and more options would be
available for human use.
Biomarker discovery, bioimaging and theranostics
The abilities to diagnose and monitor neurological diseases
have seen considerable growth in the recent decades. Nonetheless,
in understanding the mechanisms and pathology of neurodegen-
erative diseases, the development of strategies to detect neurolog-
ical diseases at early stages and prior to the emergence of overt
symptoms is still a challenge for scientists and physicians in the
field. In this context, nanotechnology-based techniques have
gained tremendous interest as a tool in the efforts to improve the
effectiveness of the imaging of central nervous system (CNS)
functions and disease states as well as to advance neurosurgical
practice.Most notably is bioimaging.Magnetic resonance imaging
(MRI) has emerged as the most important tool in the diagnosis of
brain disorders. Positron emission tomography (PET) imaging is
not far behind and has already allowed improved understanding of
the time course of a range of nervous system disorders including
for the pathophysiology of Alzheimer’s disease (AD). This has
been seen through the application of radiolabeled amyloid
ligands.4–6
Nanoparticles containing iron, gadolinium and manganese
were studied extensively as contrast agents. Among them
superparamagnetic iron oxide (SPIO) nanoparticles have gar-
nered interest due to their large surface area, magnetic properties
and low toxicity. Biocompatible SPIO nanoparticles consist of a
crystalline iron oxide core (in the form of magnetite, Fe3O4, or
maghemite, γFe2O3) encased in polymer or a coated monomer
(Figure 1, upper panel).7,8 The particles can be classified
according to their size in several categories: particles with a mean
diameter of 50 to 180 nm, referred to as standard SPIOs (e.g.
ferumoxides coated with dextran); ultra-small SPIO (USPIOs)
nanoparticles with a diameter of 10 to 50 nm; and very-small
SPIO (VSPIOs) nanoparticles less than 10 nm in diameter.9 The
nature of the surface coatings determines the physical and
biologic properties such as the overall size, surface charge,
coating density, toxicity and degradability. These affect the fate
of SPIO in body fluids and cells10. The nonspecific uptake of
SPIO nanoparticles by the reticuloendothelial system (RES) has
found clinical application for imaging liver tumors11,12 and
lymph nodes.13 Ferumoxytol, the USPIO nanoparticles coated
with polyglucose sorbitol carboxymethyl ether approved for
intravenous iron replacement therapy in patients with chronic
kidney disease,14 was recently investigated as anMR contrast for
brain tumors.15,16 Unlike gadolinium-based agents, contrast
enhancement of brain malignancies with ferumoxytol requires
intracellular uptake by mononuclear phagocytes (MPs; perivas-
cular macrophages and microglia) and reactive astrocytes with
maximal signal enhancement at 24-48 h after injection.9 The
extended USPIO residence time is believed to promote their
uptake by circulating cells. This suggests that USPIOs, combined
with perfusion-weighted imaging can accurately gauge tumor
progression.
Since MPs are present in a range of intracranial pathologies
from glial tumors to many inflammatory disorders, ferumox-
ytol and other USPIO may be useful for imaging diseases.
Labeling of circulating monocytes by systemic administration
of USPIO nanoparticles was applied to spatiotemporal profiles
of MP infiltration in stroke models.17,18 Studies demonstrated
delayed influx of blood-borne monocytes in affected brain
regions. The potential of using ferumoxtran-10 (USPIO
coated with dextran) for imaging ischemic lesions in patients
suffering from stroke was evaluated.19 Contrast enhancement
was observed primarily within the infarcted brain region
attributed to the USPIO nanoparticle-labeled macrophage brain
infiltration. The latter was supported by a combination of
gadolinium-enhanced and USPIO nanoparticle-enhanced
MRI.17,18 Similar observations were reported by Beckmann et
al20 in studies of cerebral amyloid angiopathy in amyloid precursor
protein mouse AD models. Systemic administration of SPIO
improved the MRI detection of microvascular lesions in the brains
of the mice, and also led to the labeling of additional microvascular
alteration sites. For AD, it was suggested that monocytes take up
SPIO nanoparticles in the circulation then penetrate the brain after
attraction by chemokines produced by amyloid beta (Aβ)-stimu-
lated glia. This is true in inflammatory diseases of the nervous
system. Indeed,macrophage activity can be visualizedwithUSPIO
nanoparticles using MRI tests in patients with relapsing–remitting
multiple sclerosis.21 Alternatively to labeling circulating mono-
cyte-macrophages, visualization of activity may be achieved with
isolated cells loaded with SPIO nanoparticles through in vitro
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Figure 1. Polymer composition strategies for nanomedicines. A range of nanomedicines has been developed for drug delivery. These include particle platforms
that have versatile and tunable composites for large surface to volume ratios, an optimal surface charge, hydrophobicity, and controllable particle shape and size.
Descriptions are made for cargos and surface targeting modifications. The availability of enhanced imaging modalities has facilitated bioimaging and
theranostics applications. These are illustrated and represent the development and use of polymer drug conjugates, dendrimers, micelles, liposomes, solid lipid
nanoparticles and polymeric nanoparticles (Upper Panel). The abilities of these nanoformulations to cross the blood–brain barrier and target specific neural and
glial cells underpin their therapeutic activity in disease and drug storage capacities (Lower Panel).
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incubation prior to systemic administration. Such a strategy has
been applied in stroke models to depict inflammatory cell
biodistribution.22
Multifunctional modifications of SPIO nanoparticles with
specific ligands such as antibodies, peptides, aptamers and other
targeting molecules offer the ability to monitor SPIO nanoparticle
accumulation at the disease site (Figure 1, lower panel). This results
in enhanced contrast and improved diagnostics. For example, SPIO
nanoparticles conjugated with chlorotoxin (a neurotoxin known to
target glioma) show increased uptake in glioma cells and are being
developed to improve imaging of brain tumors.23,24 Polyethylene
glycol (PEG)-coated USPIO nanoparticles chemically coupled
with Aβ1-42 peptide have provided the opportunities for
simultaneous targeting and imaging of amyloid plaques in AD
transgenic mice. This is seen following intravenous injection
without the need to co-inject an agent to transiently open the
BBB.25 The amyloid plaques detected by longitudinal bioimaging
were confirmed with matched histological sections. Such systems
are very useful for early diagnosis and also for direct measurements
of anti-amyloid therapies.
In sites of inflammation in stroke, multiple sclerosis, and
HIV-dementia, circulating blood leukocytes are the first to
migrate across activated endothelium. In particular, vascular cell
adhesion molecule-1 (VCAM-1) plays an important role in
leukocyte recruitment to the brain.26–28 Thus, targeting contrast
agents to adhesion molecules in inflamed, activated cerebral
endothelium is a potent strategy for early diagnosis. The
feasibility of VCAM-1 visualization in acute brain inflammation
was demonstrated with VCAM-1 antibody conjugated to
microparticles of iron oxide (VCAM-MPIO).29,30 In this case,
the application of micron-size of MPIO allowed delivery of a
high iron payload to the targeted sites of disease. In addition, due
to their size, micron-size SPIO (MSPIO) particles are less
susceptible than USPIO to extravasation or non-specific uptake
by endothelial cells, and therefore retain specificity for molecular
targets. VCAM-1-targeted MRI revealed that pre-symptomatic
lesions could be quantified in an experimental autoimmune
encephalomyelitis (EAE) of multiple sclerosis when found
undetectable by gadolinium-enhanced MRI.31 An alternative to
VCAM-1 targeting is the direct detection of neuroinflammation
by targeting E- and P-selectins. This demonstrates the fact that
intercellular adhesion molecules are up-regulated as part of host
response to injury.32 Van Kasteren et al designed glyco-USPIO
decorated with a biomarker ligand sialyl LewisX which showed
excellent targeting to activated endothelium and allowed
pre-symptomatic in vivo brain imaging of brain diseases in
several clinically relevant animal models.33 Similarly, USPIO
nanoparticles coated with a short heptapeptide (IELLQAR) that
target selectin binding sites34 were successfully used for
mapping E-selectin expression following traumatic brain
injury.35
Nanoparticles based on biodegradable poly(n-butyl cyano-
acrylate) (PBCA) coated with the surfactant polysorbate 80
were investigated as carriers for drug delivery to the brain. The
ability of these nanoparticles to bypass the BBB has been
attributed to polysorbate-80 mediated affinity for apolipopro-
teins B and E and the subsequent transcytosis through
low-density lipoprotein receptors present on brain endothelial
cells.36,37 This mechanism was utilized to deliver BBB-im-
permeable molecular imaging probes into the brain for
visualization of amyloid plaques.38 Further, MRI of wild type
mouse brain revealed contrast enhancement of brain parenchy-
ma after intravenous administration of PBCA nanoparticles
loaded with gadobutrol, a gadolinium-based contrast agent
routinely used in humans for imaging anatomical lesions.
Similarly, PBCA nanoparticles were utilized for the brain
delivery of radiolabeled amyloid-affinity chelator,
125I-clioquinol, a derivative of quinoline imaging probes.39
Nanoparticulate encapsulation of 125I-clioquinol into PBCA
nanoparticles resulted in significantly greater brain uptake,
enhanced retention of the drug and labeling of amyloid deposits
in AD transgenic mice. These data collectively indicate the
future potential of nanocarrier-mediated delivery of molecular
imaging probes to improve diagnostic specificity.
The use of nanotechnology-based approaches for cell
therapy and tissue engineering has shown promise in brain
and spinal cord injury. Stem cells have been shown to
selectively target injured brain and spinal cord tissue and
improve functional recovery (Figure 2).40,41 The ex vivo
loading of cells with magnetic nanoparticles allowed the in vivo
tracking and monitoring of grafted cells in the host organism
with MRI after transplantation. Successful in vivo detection
and migration monitoring of SPIO-labeled cells were demon-
strated in numerous preclinical studies related to implantation
of hematopoietic, mesenchymal or neuronal cells in the
CNS.40,42–44 Clinical trials based on this approach involved
tracking autologous neural stem cells by MRI in traumatic head
injury and bone marrow stem cells in chronic spinal cord injury
and were shown to be safe and effective.45,46 Despite the
encouraging results of initial trials, cell tracking using SPIO
labels is limited by dilution of contrast agent during cellular
proliferation, possible transfer of label from dying cells to
surrounding endogenous cells (e.g. macrophages or microglia),
and inability to discriminate between live and dead labeled
cells. Thus, interpretation of signal changes during long-term
MRI cell tracking might be difficult and requires caution.47 In
addition, the clinical MRI agents Feridex® (Endorem) and
Resovist® are no longer commercially available. Feridex was
discontinued by AMAG Pharma in 2008, while Resovist was
approved for the European market in 2001, but production was
abandoned in 2009; thus new SPIO suitable for clinical
applications will have to be developed. Li et al review the
approaches for the development of MR contrast agents suitable
for cell labeling.48
Semiconductor fluorescent quantum dots (QDs), nanoscale-
sized particles, are used extensively for visualization and
tracking of living cells. Manipulations of the core material and
size allow synthesis of a wide array of QDs emitting at various
wavelengths, including the near-infrared region, which is
optimal for deep-tissue imaging.49 The long-term stability
and brightness of QDs as well as the possibility for attachment
of different bioactive molecules to their outer shells make them
perfect candidates for in vitro and in vivo targeting and
imaging. For example, diffusion dynamics of glycine receptors
in living spinal neurons were analyzed using single-QD
tracking.50 In this study, the fluorescence and electron
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microscopy images were acquired with the same probes, which
provided both the temporal dynamics and high-resolution
localization of the diffusing receptors in the neuronal
membrane. Wang et al demonstrated the feasibility and
specificity of using antibody-labeled QDs for rapidly visual-
izing epidermal growth factor receptor expression in human
brain tumor cells and in surgical frozen section slides of glioma
tissue.51 Recently, Feng et al developed QDs conjugated with
an anti-Aβ antibody to track the state of Aβ accumulation in
vivo in a mouse model of AD.52 While QD-based optical
imaging represents a valuable tool to address cellular and
molecular questions of interest, one of the remaining issues
Figure 2. Pathogenesis and nanomedicine treatment of neuroinfectious diseases. Disease in the CNS is caused, in largest measure, by genetic, degenerative,
immune and infectious events. This results in neuronal injury or death, astroglial and microglial activation, or infection with consequent secretion of
inflammatory neurotoxic mediators. Nanomedicines can directly cross the blood–brain barrier, affect physiological response barrier function or be carried
within circulating immunocytes (monocyte/macrophages and lymphocytes) and stem cells. Once inside the brain, they release their cargo and affect ongoing
disease processes leading to clearance of microbial infections, neuronal repair and/or anti-inflammatory responses leading to restoration of glial
homeostasis.
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with QD probes is in vivo toxicity. Modification of the surface
of QDs by PEG or other polymers significantly improved their
biocompatibility; however, the long-term fate of polymer-
coated QDs in living organisms is not fully understood. Safety
concerns need to be addressed before applications of QDs can
be translated into human clinical use.
Recently, the arsenal of nanoparticle-based technologies has
been further expanded by the design of multifunctional
constructs combining diagnostic and therapeutic functions
within the same nanocarrier (Figure 1, upper panel). These
“theranostic” platforms enable a noninvasive assessment of the
pharmacokinetics, tissue biodistribution and accumulation of
drugs at the target site (Figure 1, lower panel). Such an
approach can be used to optimize the drug delivery systems and
treatment regimens in order to achieve maximal therapeutic
efficacy and minimize drug-induced side effects. By doing so,
theranostic nanoparticles might also contribute to the develop-
ment of “personalized” treatment options. Numerous exciting
examples were developed in recent years, especially for the
treatment of cancer.53,54 Reddy and colleagues have developed
multifunctional polyacrylamide-based nanoparticles consisting
of a surface-localized tumor vasculature targeting F3 peptide, an
encapsulated photosensitizer (Photofrin) and an iron oxide
imaging agent. Serial MRI was used for determination of
pharmacokinetics and distribution of nanoparticles within the
tumor. A combination treatment of F3-targeted nanoparticles
followed by photodynamic therapy in glioma-bearing rats
showed a significant improvement in survival rate in treated
animals that were found tumor-free at the end of the study.55 In
another study, researchers demonstrated that dendrimer-grafted
gadolinium-functionalized nanographene oxide nanoparticles
carrying epirubicin and miRNA can be detected by MRI to
identify the tumor area and quantify the concentration of
therapeutics within the tumor in a mouse glioma model.56 The
capacity of theranostic agents to delineate the peri-infarct region
and achieve a therapeutic effect in brains of ischemic injured
animals was also demonstrated.57 These investigators prepared
stealth immunoliposomes carrying the drug citicoline and a
contrast agent, a gadolinium-labeled lipid. HSP72 protein, an
inducible form of HSP70 that translocates to the cellular
membrane under stress conditions such as ischemia, was
selected to specifically target the peri-infarct tissue.58 Using
MRI, they found that after intravenous administration, about
80% of anti-HSP72 liposomes were located on the periphery of
the ischemic lesion, and animals treated with citicoline
encapsulated in these liposomes presented significantly smaller
lesion volumes compared to controls. These findings demon-
strate that targeted theranostic nanoparticles represent an
interesting platform for noninvasive monitoring of the effec-
tiveness of the therapy. Although the data of theranostic
approaches being used to target areas located inside the brain
parenchyma are currently limited, these examples clearly
demonstrate the potential of nanotheranostics to bring much-
needed treatments for neurological diseases.
Biomarkers are molecules that indicate the biological status
of a disease59 and, therefore, can provide invaluable informa-
tion for clinical diagnosis such as monitoring response to
treatment, as well as, aid in the development and evaluation of
novel therapies. Sensitive and accurate detection of biomarkers
in human body fluids could offer essential input to early
diagnosis for neurological diseases. In the past decade, various
nanomaterials (gold (Au) nanoparticles, QDs, SPIO, carbon
nanotubes and nanowires) have been extensively studied
to improve the sensitivity and specificity of biomarker
detection.60–63 For example, a bio-barcode amplification
assay based on a sandwich process involving oligonucleoti-
de-modified Au nanoparticle and magnetic microparticles,
both functionalized with antibodies against a specific antigen,
was utilized for ultrasensitive detection of soluble amyloid-β-
derived diffusible ligands (ADDLs) in cerebral spinal fluid
(CSF) at clinically relevant concentrations.64 Elevated con-
centrations of ADDLs were detected in the CSF of AD patients
compared with CSF from non-demented controls. Another
sandwich assay was developed for fast detection of Alzhei-
mer's tau protein using a combination of hybrid magnetic
nanoparticles functionalized with monoclonal anti-tau anti-
bodies and polyclonal anti-tau immobilized Au nanoparticles
as the recognition and surface-enhanced Raman scattering
component, respectively.65 Ultrasensitive immunosensors for
detection of Aβ peptides based on surface plasmon
resonance66 or scanning tunneling microscopy-based electrical
detection67 utilized specific monoclonal antibody fragments
immobilized on the surface of Au nanoparticles as recognition
elements. Yang et al synthesized and characterized SPIO
coated with antibodies against Aβ-40 or Aβ-42 and employed
them as an immunoassay platform.68 In combination with
immunomagnetic reduction technology, these biofunctiona-
lized SPIO targeted Aβs with high specificity and exhibited
ultralow detection limits (~10 pg/mL). Furthermore, levels of
Aβ-40 or Aβ-42 peptides detected in blood plasma samples
from normal and AD patients correlated with clinical
diagnosis. Aβ screening methodology based on the electro-
chemical sensing of saccharide–protein interactions has also
been reported.69 The densely packed sialic acid areas for
recognition of Aβ were arranged on the surface of Au
nanoparticles electrodeposited on a screen-printed carbon
strip. The intrinsic oxidation signal of tyrosine residues from
captured Aβ peptides was detected and monitored using
differential pulse voltammetry. Neely et al demonstrated that
monoclonal anti-tau antibody-coated Au nanoparticles were
used for detection of CSF tau by employing a two-photon
Rayleigh scattering assay.70 The plasmon absorbance of the Au
nanoparticles also was exploited in the design of a colorimetric
assay for neurotransmitters involved in PD pathology.71
The exceptional optical properties of QDs also make them
useful as signal amplification agents in biomarker detection.72
Recently, core-shell CdSe/ZnS QDs were used in an assay
designed to detect apolipoprotein E (ApoE) as a potential
biomarker for AD.73 The QDs proved to be highly effective
reporters and exhibited up to a 7-fold enhancement in limit of
detection compared to a conventional enzyme-linked immuno-
sorbent assay targeting ApoE. This allowed assaying very small
volumes (1 μL) of human serum with high sensitivity and
acceptable precision and accuracy. Further fine-tuning of
microarrays for use with QDs will facilitate improved biosensing
and diagnostics.
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Other nanoparticle-based technologies have also been investi-
gated for biomarker detection. An et al exploited Au-doped
titanium oxide nanotube arrays to develop a photoelectrochemical
immunosensor for α-synuclein detection.74 A parallel approach
was proposed based on a dual signal amplification using
G4-polyamidoamine dendrimer-encapsulated Au nanoparticles
and enhanced Au nanoparticle labels.75 The designed immuno-
sensor displayed an excellent analytical performance with a
detection limit of 14.6 pg/mL for α-synuclein. Recently, vertically
aligned ZnO nanowire arrays were fabricated on 3D graphene
foam and used to selectively detect uric acid and dopamine by a
differential pulse voltammetry method at a detection limit of
1 nM.75 This method was further used to show the feasibility of
using uric acid as a biomarker in the serum of PD patients.
Apart from these examples, there are a number of other studies
that use nanomaterials for developing sensing mechanisms that
will allow detecting and measuring the concentrations of
pathogenic markers in biological samples at clinically relevant
concentrations. Although the majority of the reported data are
related to the proof-of-concept studies, the current findings
strongly suggest that nanotechnology has a real potential to
contribute to early detection, diagnoses and treatments of
neurodegenerative diseases.
Nanomedicines for infectious diseases
Nanoneuromedicines are being developed to increase drug
penetration into sites of active microbial infection while limiting
systemic toxicities. Longer acting medicines would also improve
regimen adherence. Thus, to facilitate drug therapeutic efficacy by
improving pharmacokinetics and disease region-specific nervous
system drug biodistribution as well as immune-directed microbial
clearance best defines the field of infectious disease-linked
nanoneuromedicine. The overarching goal is to actively target,
and then eliminate sites of persistent infection, inflammation or
degeneration.76–78 In recent years, a number of nanomedicines
were developed for the treatment, detection and prevention of
Figure 3. Targeted nanoformulated drug delivery for infectious diseases of the nervous system. Nanoformulated antimicrobial drugs can be targeted to brain
endothelial cell receptors such as insulin, leptin, transferrin and epidermal growth factor receptors to promote transfer across the blood–brain barrier (BBB).
They can also be targeted to monocyte-macrophage receptors such as folate, CD4, mannose and CD44 receptors to promote cell uptake for macrophage-based
drug delivery across the BBB. The nanoformulated antimicrobial agent that is decorated with the appropriate ligand for the targeted cellular receptor can be
administered systemically with the insurance it will find either a BBB-target cell or an appropriate carrier cell such as MPs that support transport across the BBB.
Once inside the brain the drug cargo can be released from free nanoparticles or macrophages to facilitate resolution of microbial infection.
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infectious diseases.79 The platform has focused on liposomes,
polymeric nanoparticles, dendrimers, micelles and SLNs to
improve water-solubility of poorly-water-soluble drugs and
subsequently enhance drug stability to sites of infection. Specific
drug targeting to endothelial cell receptors and use of cell-based
carriage of nanomedicines serve to facilitate CNS delivery
(Figure 3).
The CNS infections where nanomedicines are currently being
developed include bacterial meningitis, rabies, malaria and HIV.
Research is active in models of human disease and in
translational research. For example, treatment strategies for
Staphylococcus aureus and Cryptococcus neoformans meningi-
tis in rabbits were successful with self-assembled cationic
antimicrobial peptides of cholesterol-conjugate G3R6TAT.
80,81
The manufactured particles easily crossed the BBB and were
shown to be equally effective as vancomycin and amphotericin B
in attenuating meningeal infections and their sequelae without
affecting liver function or causing imbalances in blood
electrolytes. Both are known complications in treating bacterial
and fungal disease. Other studies showed that delivery of
vancomycin into a drug-resistant S. aureus strain using a folic
acid-conjugated chitosan nanocarrier improved delivery of the
medicine,82 highlighting the notion that nanoparticle delivery
could positively affect treatment outcomes for multidrug
resistance in bacteria. Benefits were seen with such an approach
in reducing oxidative stress that follows S. aureus infections.
Indeed, diminished lipid peroxidation, protein oxidation, nitrite
generation, DNA damage and glutathione were seen with the
emergence of antioxidant enzymes.
Adjunctive therapies are often used in combination with
antimicrobials to reduce the inflammatory events that contribute
to CNS damage and long-term impairments associated with CNS
infectious diseases;83–85 however, the high incidence of adverse
side effects with corticosteroids limits their use.83 In a recent
study, nano-sterically stabilized liposomal formulations of the
glucocorticoid β-methasone hemisuccinate were used in con-
junction with artemisone to enhance the efficacy of the
antiplasmodial in an experimental mouse model of cerebral
malaria with no glucocorticoid-related side effects.86 Of
importance, the liposomal formulation of the glucocorticoid
resulted in accumulation of the drug in the brains of infected
mice, but not healthy mice. The use of nanoparticles for delivery
of anti-inflammatory agents has also been described for
Escherichia coli-induced meningitis87 and demonstrated that a
water-soluble malonic acid derivative of carboxyfullerene could
reduce CNS levels of TNFα and IL-1β and inhibit neutrophil
infiltration across the BBB. In other reports, nanoparticle
systems comprised of dendrimers with multiple reactive surface
groups have also demonstrated anti-prion activity in part through
alteration of the conformation of misfolded prion proteins
(reviewed by McCarthy et al88), and maltotriose modified poly
(propyleneimine) dendrimers have been shown to be capable of
crossing the BBB.89
Ultimately, the best treatment for controlling CNS infec-
tious disease is vaccination. Nanoparticles have been devel-
oped for improving the immunogenicity and efficacy of
vaccines against several CNS infectious diseases. A dendri-
mer–DNA complex (dendriplex) using a plasmid vaccine
construct of the rabies virus glycoprotein gene was complexed
with a novel poly(ether imine) (PETIM) dendrimer and used to
immunize mice that were subsequently challenged with a
standard rabies virus strain.90 These mice demonstrated 4-fold
improved viral titers 14 days after immunization compared to
mice immunized with the unformulated plasmid viral construct.
In addition, all mice receiving the dendriplex vaccine compared
with 60% of the mice receiving the unformulated vaccine
survived viral challenge. In another study, Knuschke et al used
functionalized triple-shell calcium phosphate (CaP) nanoparti-
cles as carriers for toll-like receptor 9 ligand CpG and antigenic
peptides to induce a robust immune response and protection
from Friend virus-induced splenomegaly and reduction of viral
load.91 This system provided a proof of concept for the
development of nanoparticle-based vaccines for retroviral
infection.91
Nanoparticle-based detection systems are being developed
to provide early and sensitive means for diagnosis of
infectious disease. Early diagnosis is critically important for
effective treatment of CNS infections. Reddy and coworkers
recently described the use of Au nanoparticles to enhance
detection of meningococcal antigen by an acoustic wave
immunosensor method.92 By binding the cell surface outer
membrane protein 85 (OMP85) of N. meningitides to Au
nanoparticles and interacting these complexes with antibodies
immobilized on a PVDF-coated quartz crystal microbalance,
detection of as little as 312 ng/ml OMP85 in blood or CSF
could be readily observed.
Various nanoparticle-based approaches have also been
described for treatment of HIV infection in the CNS. These
notably include drug polymer conjugates, dendrimers, mi-
celles, liposomes, SLNs, nanosuspensions, polymeric nano-
particles and cell-mediated nanoparticle delivery.93 Of note,
improved CNS bioavailability of efavirenz and an increase in
the relative exposure index for the drug were described using
intranasal administration of efavirenz-loaded Pluronic® block
copolymer (poly(ethylene oxide)-poly(propylene oxide) poly-
meric) micelles.94 Pluronic® block copolymers can inhibit
efflux transporters (P-glycoprotein and multidrug resistan-
ce-associated protein) on brain microvascular endothelial cells,
thus facilitating delivery of drug across the BBB.95 Liposomal
formulations are used to improve pharmacokinetics of both
hydrophobic and hydrophilic drugs. Jin and coworkers
demonstrated that liposomal formulations of a zidovudine
prodrug (AZT-myristate) provided a 2-fold increase of drug in
the brain compared to an equivalent dose of free AZT.96
Liposomal formulations targeted to transferrin and insulin
receptors on endothelial cells are also being explored for
enhanced delivery of drugs, including antiretrovirals, to the
brain.97,98 In other studies, Saiyed and coworkers demonstrated
improved penetration of magnetic azidothymidine 5’-triphos-
phate liposomal nanoformulations upon application of an
external magnetic field.99 Cationic nanogel formulations of
nucleoside reverse transcriptase inhibitors (NRTIs) decorated
with the peptide binding (AP) brain-specific ApoE receptor
exhibited improved CNS antiviral activity compared to
non-formulated NRTIs and with low neurotoxicity.100 SLNs
are also being investigated for improved antiretroviral drug
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pharmacokinetics and CNS delivery. Kuo and Su demonstrated
that stavudine, delavirdine and saquinavir encapsulated in
SLNs more readily passed across an artificial BBB compared to
unencapsulated drugs.101 In other in vitro studies, Kuo and Ko
used the insulin-like peptidomimetic monoclonal antibody,
83-14 MAb, as a targeting moiety to improve penetration of
saquinavir SLNs across an artificial BBB.102 While these in
vitro results are promising, supportive in vivo studies are
needed to demonstrate the utility of targeted SLNs for
improved CNS antiretroviral therapy (ART) delivery.
To extend circulation longevity of nanomedicines that are
targeted for specific diseases such as cancer, many drug delivery
systems have been designed to evade the immune system, thus
improving delivery of drug to the desired target while reducing
untoward immune reactivity.76 Over the last decade the strategy of
targeting nanoparticles to MPs, lymphocytes and stem cells to use
them as Trojan horses for delivery of anti-infective medicines has
been explored to facilitate drug delivery for a variety of infectious
and neurodegenerative diseases.77,103 Our own laboratories have
developed the concept of MP delivery of nanoART to extend
circulating drug levels and target sites of HIV replication including
the CNS.104–106
Targeted cell-based delivery is also being developed as a
means of carrying drug nanoparticles across biologic barriers,
such as the BBB. The phagocytic and chemotactic capabilities of
MPs can be harnessed by targeted systems to deliver drugs to
CNS disease sites and to other protected sites such as lymphoid
tissue.77,103 Proof of concept was demonstrated for delivery of
nanoformulated catalase (nanozymes) to the CNS and for
delivery of nanoART to localized CNS HIV-1 infection in
mouse models of Parkinson’s disease (PD) and HIV encephalitis
(HIVE), respectively.105,107 CNS targeting of bone marrow
macrophages (BMM) loaded ex vivowith indinavir nanoparticles
was determined in an HIVE mouse model. BMM loaded with
indinavir nanoparticles were administered intravenously to mice
and provided indinavir release up to 14 days. Of significance,
indinavir was present in infected brain regions where there was
significant inhibition of HIV replication.105 Intracellular transfer
of nanoART fromMDM to brain microvascular endothelial cells
was confirmed in vitro by Kanmogne et al, and this transfer
could be enhanced by addition of folate on the nanoparticle
surface as a targeting ligand.108 The results demonstrated that
nanoART could transfer NP through cell-to-cell contacts, and
thus facilitate the penetration of nanoART across the BBB. By
targeting drugs to MPs, delivery can be achieved to sites of
disease or infection that are normally inaccessible to free drug
in circulation.
Of importance, however, an effective cell-based delivery
system is dependent on the normal function of the cell carrier.
Thus, for macrophages, their normal functions of phagocytosis,
migration, and release of immune-modulating cytokines and
chemokines should be maintained in nanoparticle-loaded cells.
Martinez-Skinner et al used dynamic global proteomic changes
in macrophages loaded with nanoART to identify changes
linked to immune cell migration and chemotaxis, cytokine and
chemokine production, lipid metabolism, free radical scaveng-
ing, and cell differentiation.109 Protein changes were substan-
tiated by functional assays that indicated nanoART uptake
induced a macrophage activation phenotype that is primed for
further nanoART uptake, storage and cell migration, which
would thus enhance the capacity of the cell to deliver drug to the
site of disease.109
For cell-based drug delivery, the carrier cell must deliver
sufficient amounts of therapeutically active drug to the site of
infection and disease. For this to occur, once inside the cell, the
drug must be localized in stable, non-degrading subcellular
compartments that facilitate release at the target site.110
Cationic nanoparticles decrease acidification of lysosomal
compartments, and thus are generally less likely to be degraded
than are anionic particles.103 In addition, trafficking of
nanoparticles to non-degrading endosomal subcellular com-
partments can also reduce lysosomal degradation. Our studies
on macrophage delivery of nanoART, demonstrated that
ritonavir nanoART prepared with P188, DSPE-mPEG2000,
and DOTAP as surfactants was taken up by macrophages via
clathrin-mediated endocytosis and trafficked to recycling (Rab
11+ and Rab 14+) endosomal compartments.111 Therapeuti-
cally active nanoparticles were released intact at the cell
surface. Of particular importance, active targeting of the
nanoformulated antimicrobials to specific cell compartments
not only enhanced cell storage, but also allowed the drug to be
directed to the cell compartments where the infectious agents
replicate.111 Such an effect was recently demonstrated for
nanoART; wherein, atazanavir nanoART was co-localized in the
same macrophage endosomal compartments utilized for HIV-1
replication.112 Thus, not only can nanoART be carried intact by
macrophages to sites of disease; but for microbial and viral
infections that target macrophages, the drug may also be delivered
to the site of microbial and viral replication.
Nanotechnological approaches can impact not only therapy,
but also imaging, diagnostics and theranostics to enable early
disease diagnosis coupled with therapeutics as well as morpho-
logical and/or functional imaging. Such approaches allow for
investigation of the disease progression or recovery associated
with different therapeutic approaches such as nanoparticle or
stem-cell based strategies.
Nanomedicine and neurodegenerative diseases
Neurodegenerative diseases, such as PD, AD, and amyotro-
phic lateral sclerosis (ALS), represent a wide range of
devastating progressive conditions associated with the deterio-
ration or loss of neurons in specific locations of the CNS. A
major challenge in the treatment of neurodegenerative diseases,
including PD is the restricted access of drug molecules across the
BBB. In this regard, nanotechnology-based drug delivery
strategies hold great potential in the management and treatment
of these diseases. In this section, we will discuss the current
applications of nano-based drug-delivery systems for the
treatment of neurodegenerative disorders with particular empha-
sis on PD.
As the second most common neurodegenerative disorder,
PD affects over a million Americans with an annual cost of
several billion dollars. The disease is characterized by the loss
of dopaminergic neurons in the substantia nigra pars compacta
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of the mid-brain with a drastic decrease in striatal dopamine and
its metabolites. Another important pathological hallmark of PD
is the production of intraneuronal proteinaceous cytoplasmic
inclusions called Lewy bodies, the primary structural compo-
nent of which is α-synuclein. Cardinal motor signs of PD
include resting tremor, rigidity, bradykinesia and postural
instability. It has been increasingly recognized that the
non-motor symptoms, such as sleep disturbances, depression,
cognitive impairment, anosmia, constipation and autonomic
dysfunctions precede the classic motor symptoms by several
years.113 Currently, the gold standard of treatment for PD
remains the oral administration of dopamine agonists such as
levodopa. Although levodopa provides the greatest benefit for
motor symptoms, it is unable to stop or compensate for the
continual loss of dopamine neurons. Furthermore, the effectiveness
of levodopa fades rapidly; and its long-term use often results in
serious motor fluctuations. Thus, more effective treatments for PD
patients are urgently needed.
In recent years, nanotechnology has been employed in an
effort to enhance the efficacy of PD therapy. Major advantages of
using nanosystems as drug delivery agents include specific
delivery for targeted action in the CNS, effectively overcoming
barriers to CNS, and improving the bioavailability and
therapeutic efficacy of anti-parkinsonian agents. One specific
example of nanotechnology in advanced experimental treatment
of PD is the brain-targeted delivery of dopamine. Using an
intracranial nano-enabled scaffold device implantable in the
parenchyma of the frontal lobe of the brain, Pillay and colleagues
showed that the inclusion of dopamine-loaded cellulose acetate
phthalate NPs into a binary cross-linked alginate scaffold
facilitated local dopamine delivery in a rat model.114 Recently,
systemic delivery of dopamine has been developed. Trapani et al
found that dopamine-loaded chitosan NPs were less cytotoxic
than free dopamine in vitro. In vivo brain microdialysis
experiments in rats demonstrated that intraperitoneal adminis-
tration of the dopamine-loaded chitosan NPs effectively
increased striatal dopamine levels.115,116 Unfortunately, these
studies did not explore the efficacy of administering dopamine-
loaded NPs in modulating motor activity and brain biochemical
changes in an animal model of PD. In a very recent study,
Rashed et al attempted to use polyvinylpyrrolidone-poly (acrylic
acid) (PVP/PAA) nanogels synthesized by γ-radiation-induced
template polymerization to systemically deliver dopamine to the
brain.117 Intraperitoneal administration of the dopamine-loaded
PVP/PAA nanogels improved striatal dopamine levels and
catalepsy scores in reserpine-treated rats. Significant increases
in their long-term survival and restoration of their normal activity
were also found in the reserpine-treated rats following
subchronic administration of dopamine-loaded PVP/PAA nano-
gels. Additional animal experiments performed in a rotenone PD
rat model demonstrated that dopamine-loaded PVP/PAA
nanogels improved the mitochondrial dysfunction induced by
rotenone. Nonetheless, these disease-modifying effects of
nanogel-based delivery remain preliminary and need further
confirmation.
Nanodelivery of dopaminergic agonists like levodopa,
apomorphine, ropinirole and bromocriptine is being pursued
also because of the potential to improve brain uptake and
reduce side effects associated with these compounds. Levodopa
methyl ester, a highly soluble pro-drug that is hydrolysable by
plasma esterases, was encapsulated with benserazide in poly
(lactic-co-glycolic acid) (PLGA) NPs. This method of admin-
istering levodopa successfully abolished levodopa-induced
dyskinesia in rats.118 More recently, intranasal delivery of
levodopa NPs has been explored.119 Levodopa encapsulated in
chitosan NPs was incorporated in a thermo-reversible gel
prepared using Pluronic PF127, and then delivered via
intranasal route, which increased drug levels in the brain.119
In another study, Md et al developed a system for nose-to-brain
delivery of bromocriptine-loaded chitosan NPs.120 Intranasal
administration of bromocriptine-loaded chitosan NPs effec-
tively increased brain uptake of bromocriptine and prevented
haloperidol-induced catalepsy and akinesia in a mouse PD
model. An oil-based nanocarrier system (nanoemulsion gel) for
ropinirole transdermal delivery has shown efficacy in the
6-OHDA-lesioned rat model.121 While these studies have
shown some promise in improving the bioavailability of
dopaminergic agonists, more pre-clinical validations are
needed before being applied in clinical settings.
Other targeting molecules include antioxidants,122,123
peptides,124 and neurotrophic factors. The neurotrophic factor
nerve growth factor (NGF) was absorbed on PBCA NPs coated
with polysorbate 80 to enhance its pharmacological efficacy in
the brain.125 Intravenous administration of the NP-bound NGF
prevented amnesia and improved memory in the acute
scopolamine-induced amnesia rat model. This formulation
also demonstrated significant protection against MPTP-in-
duced motor symptoms. Even combinatorial delivery of several
neurotrophic factors has been recently investigated, yielding
promising outcomes.126,127 Lectin-functionalized, polyethyl-
ene glycol–block-poly-(D,L)-lactic-co-glycolic acid NPs load-
ed with haloperidol and further functionalized with Solanum
tuberosum lectin (STL) achieved higher drug concentrations in
the striatum when administered intranasally than when
delivered by intra-peritoneal injection.128 The study also
found a significantly higher percentage of STL-functionalized
NPs present in the striatum and olfactory bulb relative to
non-functionalized NPs. To cite another example, the macro-
molecular drug urocortin peptide, when encapsulated in
odorranalectin-conjugated PEG-PLGA NPs, was able to reduce
dopaminergic neurodegeneration and subsequent behavioral
deficits in hemi-Parkinsonian rats.129 Recently, Mito-apocy-
nin, a derivative of apocynin, which is a known NADPH
oxidase inhibitor, has been shown to attenuate behavioral
deficits in LRRK2 transgenic mouse model of PD.130 Ongoing
studies are focused on encapsulating mito-apocynin with
polyanhydride nanoparticles to prolong the brain bioavailabil-
ity of the drug.
Despite the relatively early stages of their development,
overall these nanodelivery systems continue to represent a
promising new direction for PD therapy. Furthermore, most
current studies were performed in rodent models; and thus, their
therapeutic potential to treat various neurodegenerative diseases
has yet to be evaluated in pre-clinical animal models before
eventual clinical testing. Oxidative stress and neuroinflammation
have been established as major pathophysiological mechanisms
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of many neurological diseases including PD, AD and ALS.
Inflammation caused by trauma, infection or even through the
process of aging generates reactive oxygenated species and
reactive nitrogen species resulting in the activation of microglia.
While microglia help to contain the basal inflammation at
quiescent stage, they end up, during excessive activation,
secreting more pro-inflammatory cytokines including TNF-α.
Both neurons as well as glial cells produce antioxidants.131
However, the persistence of free radicals beyond the pool of
available antioxidants leads to neurodegeneration and subse-
quent neurological symptoms. Currently, efforts are being
made to develop and transport naturally occurring and
synthetically made antioxidants as well as neuroprotective
drugs to the brain.
A major drawback of using such antioxidants alone is their
failure to cross the BBB as well as the inability to target deeper
areas of the brain such as the hippocampus, midbrain and brain
stem. Hence larger and repeated doses of the drug are needed to
elicit a protective response. Drugs encapsulated in nanoparticles,
on the other hand, can effectively cross the BBB owing to their
small size and in some cases, their chemistry.132,133 In addition,
surface functionalization of nanoparticles with a ligand whose
membrane receptors are present on specific neurons can help
target these nanoparticles to these neurons. For example,
PLGA-coated curcumin NPs functionalized with Tet-1 peptide
were able to eliminate amyloid aggregates.134 The Tet-1
functionalization allowed better uptake of NPs in GI-1 glioma
cells as evidenced by flow cytometry analysis; however, these
results were not validated by in vivo studies. Melanocortin-
loaded polysorbate 80-coated NPs reduced lipid peroxidation
while increasing antioxidant reactivity in various regions of the
brain.135 In another experiment, intravenous or oral administra-
tion of Dalgarin-adsorbed NPs provided analgesic effects as
assessed by the hot-plate test in mice. The same drug, when
delivered without NPs was unable to provide pain-relief, as the
drug could not cross the BBB.136 However, if the nanoformu-
lation is administered via the circulatory system, they acquire
opsonins on their surface and can be phagocytized.137 One way
to circumvent this problem is to deliver nanoparticles via
intra-nasal injections. The particles then reach the CNS via the
olfactory or trigeminal tracts. For example, nasal injection of
nimodipine (calcium channel blocker)-encapsulated methoxy
poly(ethylene glycol)-poly(lactic acid) (MPEG-PLA) NPs leads
to 1.6- to 3.3-fold higher drug concentrations in the brain than
nasal administration of the drug solution alone.138
Nanomaterials can also be therapeutically used to modulate
detrimental immune responses in the CNS. Multiple sclerosis
(MS) is an immune-mediated inflammatory disease of the CNS,
characterized by destruction of the protective myelin sheath
that insulates neurons. Recent evidence has highlighted the
possibility of using nanotechnology in MS patients as a
potential new tool to deliver drugs with immunosuppressive
activity. In a study of EAE, which is the most commonly used
experimental model for MS, Kizelsztein et al demonstrated that
encapsulation of tempamine, a stable radical with antioxidant
and proapoptotic activities, in nanoliposomes shows efficacy in
inhibiting EAE in mice.139 Later, Yeste and colleagues used Au
NPs to deliver a tolerogenic compound in combination with
oligodendrocyte antigen to dendritic cells to induce antigen-
specific regulatory T cells (Tregs). Au NPs loaded with an aryl
hydrocarbon receptor ligand and a T-cell epitope from myelin
oligodendrocyte glycoprotein (MOG35-55) promoted the gen-
eration of Tregs by dendritic cells in vitro. When injected
intraperitoneally to EAE mice, these NPs effectively increased
the Treg population and suppressed disease development.140
Using the relapsing–remitting EAE (R-EAE) in a murine Th1/
17-mediated model of EAE, Hunter et al developed a
biodegradable PLG NP as a myelin antigen carrier and showed
its efficacy in generating robust tolerance and preventing
disease development.141
Dendrimers are repetitively branched molecules with
nanometer-scale dimensions. Owing to their intrinsic ability
to localize to activated microglia and astrocytes, dendrimers
can be used against immune diseases by delivering immuno-
suppressive drugs to target tissues. For example, polyamidoa-
mine (PAMAM) dendrimers have been reported by Wang et al
to deliver the antioxidant and anti-inflammatory agent N-acetyl
cysteine (NAC) to the brain.142In vitro experiments indicated
that conjugating NAC with a PAMAM dendrimer increased its
antioxidant and anti-inflammatory properties relative to free
NAC. Subsequently, another study from the same group
demonstrated in an animal model that intravenously administered
dendrimer–NAC conjugates localized in the inflammation sites
associated with cerebral palsy, leading to reduced neuroinflam-
mation and improved cerebral palsy symptoms.143 Similarly, the
dendrimer-based strategy achieved sustained suppression of
inflammation in a model of retinal degeneration.144 More recently,
in a spinal cord injury study, Cerqueira et al showed that
methylprednisolone-loaded carboxymethylchitosan dendrimer
NPs are internalized by microglia, astrocytes and oligodendro-
cytes, modulating the release of growth factors while limiting the
titer of pro-inflammatory molecules.145 Moreover, local adminis-
tration of these dendrimer NPs to the spinal cord of Wistar rats
following lateral hemi-section lesions improved their locomotor
outcomes. In recent years, much attention has been focused on
neurological disorders (chronic traumatic encephalopathies,
CTE) that develop following single or repeated head injuries.
Repetitive mild traumatic brain injury can lead to diffuse
axonal injury as well as persistent neuroinflammation. This
persistent neuroinflammation and associated neurodegenera-
tion can lead to the development of chronic neurodegenerative
diseases. The use of nanoformulations as a potential drug
delivery platform to the CNS could prove critical in treating
CTE.146–148 Indeed, Ruozi et al have shown that cerebroly-
sin-loaded poly-lactide-co-glycolide NPs reduced brain edema
and possibly limited the degree of BBB permeability typically
seen after concussive head injury.149
Nanotoxicology
Man-made nanoparticles provide new opportunities for the
creation of new consumer products and the manufacture of new
materials for therapeutic and imaging applications as discussed
here. Likewise, their potential benefit to human health has
increased exponentially in recent years, but realizing this
761H.E. Gendelman et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 751–767
potential requires that any adverse effects to human health be
minimized and characterized.
Nanotoxicology is a new branch of toxicology that
addresses the adverse human and environmental health effects
associated with nanoparticles.150–156 The main source of
nanotoxicity comes from environmental and occupational
exposure to nanoparticles derived from metals such as copper,
magnesium, sodium, potassium, calcium and iron. A second,
more recent source of nanotoxicity stems from specialized
nanoparticles serving as novel platforms for the target-specific
delivery of therapeutics. Although their benefits tend to
outweigh their ill effects, nanotoxic and immunogenic aspects
of nanoparticles can no longer be overlooked. Upon passive
entry into the cell, the nanoparticles have direct access to the
cytoplasm and subcellular organelles. Depending on their
intracellular localization, nanoparticles can induce oxidative
stress, inflammation, DNA damage, cardiovascular effects and
coagulation.157 Nanoparticles have been shown to enter the
brain primarily by inhalation, specifically by crossing into the
brain through the olfactory nerves.158 Besides the CNS,
nanoparticles also enter the GI-tract, circulatory system, liver,
kidney, spleen and lymphatic systems. Diseases such as
asthma, bronchitis, emphysema, lung cancer, neurodegenera-
tive diseases, Crohn's disease, colon cancer, arteriosclerosis,
blood clots, arrhythmia and heart diseases, systemic lupus
erythematosus, scleroderma, and rheumatoid arthritis as well as
liver and spleen diseases are all associated with nanoparticle
toxicity.158–160
Metal nanoparticles are particularly toxic to the CNS.
Adverse neurological effects due to occupational exposure of
non-particulate manganese (Mn), aluminium (Al) and iron
are relatively well known. For example, chronic exposure to
Al and iron has been linked to both PD and AD.161 Mn
neurotoxicity is now clearly linked in humans.162,163 In the
condition known as manganism, occupational exposure to
Mn in miners and welders results in psychiatric and motor
disturbances, with symptoms resembling those of idiopathic
PD and that contribute to its etiopathogenesis. Currently, Mn
nanomaterials are being pursued in metallurgic and chemical
sectors;164 and therefore, neurotoxicological research on
emerging Mn nanoparticle technologies are urgently
needed.164
Our own recent work characterizing the neurotoxicological
effects of Mn nanoparticles on dopaminergic neuronal cells
suggests that environmental exposure to certain metallic
nanoparticles may cause serious health problems in humans.165
Thus, a systematic characterization of potential adverse effects of
nanomaterials will ultimately help formulate benign nanoformu-
lations for human applications.
Conclusions and outlook
Nanomedicine offers exciting possibilities to overcome the
significant challenges associated with diagnosis, imaging and
therapies to address the malfunction of the nervous system. This
is a broad area of research with enormous potential and current
efforts represent just the tip of the iceberg.
Nanoscale systems are extremely promising for safe,
effective, targeted/site-specific, and sustained delivery of anti-
inflammatory and immunomodulatory agents, growth factors
and other bioactive molecules to treat neurodegenerative
disorders and infectious diseases. Nanomedicine enables
therapeutics and imaging agents to effectively cross the blood
brain barrier. In this context, immunoprotective approaches
harnessing the immune system through nanotechnology to
address neurodegenerative disorders and traumatic brain injury
are very novel and can provide a new paradigm for the treatment
of such conditions.
While therapies represent an important aspect of nanoneur-
omedicine, diagnostics as well as imaging can benefit enor-
mously from recent developments in this new field as well.
Delivery of therapeutics as well as imaging and contrast agents
needs to overcome some similar challenges such as being able to
traverse the BBB. Advances in delivery of therapeutics can lead
to better diagnostics, better delivery of imaging agents and
development of new theranostics as well. Much of the work in
this area so far has been conducted in various animal models; and
showing efficacy in clinical studies, while addressing any
potential nanotoxicological issues, is the next important step in
moving this field forward.
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